Journal
Compounded vs Brand Tirzepatide: Legal and Evidence Differences
No equivalence language
An FDA-approved product has been reviewed for safety, effectiveness and manufacturing quality before marketing. A compounded preparation has not been reviewed at all. It is not a generic, is not therapeutically equivalent as a matter of law, and cannot be substituted for the brand. No generic tirzepatide or semaglutide exists.
Three categories, routinely collapsed into one
An approved drug has been through premarket review: the FDA examined safety, effectiveness and manufacturing quality, and approved specific labelling for specific indications.
A generic is a copy of an approved drug that demonstrated bioequivalence and was itself approved. Generics are substitutable by law precisely because that equivalence was established. No generic tirzepatide or semaglutide exists.
A compounded preparation is prepared by a pharmacy or outsourcing facility. It receives no premarket review of safety, effectiveness or quality. It is not approved, it is not a generic, and it is not therapeutically equivalent as a matter of law.
Marketing that describes a compounded product as "generic Zepbound" or "the same as Wegovy" is making a legal claim that is false, not using loose language.
What compounding is actually for
Compounding exists for patients whose needs an approved product cannot meet — an allergy to an excipient, a formulation a manufacturer does not make, a dose not commercially available. Compounding a copy of an available approved product is generally not permitted, which is why the shortage listings mattered so much: a shortage temporarily changes that.
Both shortage listings for these molecules have been resolved, and the FDA has proposed excluding them from the 503B bulks list. The surviving route requires a prescriber to document a clinical difference for the individual patient — which is what "personalised dosing" programmes are, in regulatory terms.
Where the evidence sits
Every efficacy figure in this field — SURMOUNT, STEP, SELECT, SURPASS — comes from a trial of an FDA-approved subcutaneous injection. None was collected on a compounded preparation, a microdose or an ODT.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Two specifics worth knowing
Salt forms. Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has stated they are not appropriate for compounding. Ask which form your prescription uses.
Accreditation is not approval. A state licence, an FDA facility registration and a voluntary accreditation are three different things, and none of them is approval of a product.
If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Independent price verification | not verified | not verified |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
Questions readers actually ask
Is compounded tirzepatide a generic?
No. No generic tirzepatide exists. Compounded preparations are not approved, not bioequivalence-tested and not substitutable by law.
Is compounding illegal?
No. Compounding is lawful under defined conditions. Compounding copies of an available approved product is the part that is constrained, and the conditions that permitted it at scale have narrowed sharply.
What is the salt form issue?
Semaglutide sodium and semaglutide acetate are different substances from the semaglutide base in approved products. The FDA has said they are not appropriate for compounding.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
GLP-1 Tirzepatide Review. “Compounded vs Brand Tirzepatide: Legal and Evidence Differences.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/compounded-vs-brand-legal-differences/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.